Impact of acetylsalicylic acid in patients undergoing cerebral aneurysm surgery – should the neurosurgeon really worry about it?
| Autor: | Michael Luchtmann, Ali Rashidi, I. Erol Sandalcioglu, Nadine Lilla, Martin Skalej |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Heart disease medicine.medical_treatment media_common.quotation_subject 03 medical and health sciences 0302 clinical medicine Hematoma Aneurysm 030202 anesthesiology Acetylsalicylic acid medicine Humans Postoperative hemorrhage 610.72 Stroke Retrospective Studies media_common Aspirin business.industry Clipping Intracranial Aneurysm General Medicine Clipping (medicine) medicine.disease digestive system diseases Aneurysm surgery Neurosurgeons surgical procedures operative Anesthesia Original Article Surgery Neurology (clinical) Neurosurgery Worry business Cerebrovascular surgery Platelet Aggregation Inhibitors 030217 neurology & neurosurgery |
| Zdroj: | Neurosurgical Review |
| ISSN: | 1437-2320 0344-5607 |
| Popis: | There has been an increase in the use of acetylsalicylic acid (ASA, Aspirin®) among patients with stroke and heart disease as well as in aging populations as a means of primary prevention. The potentially life-threatening consequences of a postoperative hemorrhagic complication after neurosurgical operative procedures are well known. In the present study, we evaluate the risk of continued ASA use as it relates to postoperative hemorrhage and cardiopulmonary complications in patients undergoing cerebral aneurysm surgery. We retrospectively analyzed 200 consecutive clipping procedures performed between 2008 and 2018. Two different statistical models were applied. The first model consisted of two groups: (1) group with No ASA impact - patients who either did not use ASA at all as well as those who had stopped their use of the ASA medication in time (> = 7 days prior to operation); (2) group with ASA impact - all patients whose ASA use was not stopped in time. The second model consisted of three groups: (1) No ASA use; (2) Stopped ASA use (> = 7 days prior to operation); (3) Continued ASA use (did not stop or did not stop in time, ASA impact group vs. No ASA impact group: OR = 1.0516 [0.1187; 9.3132], p = 1.000; RR = 1.0015 [0.9360; 1.0716]). Cardiopulmonary complications were significantly more frequent in the group with ASA impact than in the group without ASA impact (p = 0.030). In this study continued ASA use was not associated with an increased risk of a postoperative hemorrhage. However, cardiopulmonary complications were significantly more frequent in the ASA impact group than in the No ASA impact group. Thus, ASA might relatively safely be continued in patients with increased cardiovascular risk and cases of emergency cerebrovascular surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink